Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of nemolizumab vial vs DCS formulations in healthy volunteers
jRCT2031210654Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of nemolizumab in prurigo nodularis (PN) (2 arms), sponsored by Maruho Co., Ltd. Primary endpoint: Pharmacokinetic parameters. Started Mar 2022; status: completed.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on jRCT2031210654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210654.